| Project/Area Number |
23590640
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
MINAMI Hironobu 神戸大学, 医学(系)研究科(研究院), 教授 (60450574)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MUKOUHARA Toru 神戸大学, 医学部附属病院, 特命准教授 (80435718)
YOSHIDA Masaru 神戸大学, 大学院医学研究科, 准教授 (00419475)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 乳がん / 化学療法 / 末梢神経毒性 / 抗腫瘍効果 / プロテオーム解析 / パクリタキセル / 乳癌 / プロテオーム / 臨床薬理学 |
|---|
| Research Abstract |
Proteomics was investigated to identify proteins which were associated with efficacy and toxicities of the primary systemic chemotherapy with weekly paclitaxel in patients with early breast cancer. Paclitaxel was given at 80 mg/m2, and plasma was obtained before the treatment and 6-8 days after the first administration of paclitaxel. Toxicities were monitored weekly. Among 20 patients, good PR was achieved in 4 and grade 2 or greater peripheral neuropathy was observed in 9. The greatest difference between responders and non-responders was observed in concentrations of Fibulin-1, and Dynein heavy chain 7 showed the greatest correlation to peripheral neuropathy. Patients with a lower concentration of Dynein heavy chain 7 was associated with a higher risk of peripheral neuropathy, and its concentration was increased after the start of the treatment in 5 of 7 patients who experienced neuropathy. Fibulin-1 was also significantly associated with peripheral neuropathy.
|
